Verona to present RPL554 at the ATS Conference

Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases, today announces that it will present three abstracts at the American Thoracic Society (ATS) 2016 International Conference in San Francisco, USA between 13-18 May. The abstracts will cover clinical data related to the Company’s lead drug RPL554, a novel inhaled PDE3/PDE4 inhibitor with both bronchodilator and anti-inflammatory properties, currently in development as a nebulised treatment for acute exacerbations in chronic obstructive pulmonary disease (COPD) patients in a hospital or home-care setting.

All three posters support Verona Pharma’s view that RPL554 could become an important, novel and complementary inhaled medicine for the treatment of respiratory diseases such as COPD, asthma, and cystic fibrosis.

All abstracts and details on timings can be accessed through the ATS website: http://conference.thoracic.org/

The title, timing and location of the poster presentations are as follows:

**Abstract ID 13130**

**Authors:** L. Bjermer, J. Stewart, K. Abbott-Banner, K. Newman

**Title:** RPL554, a First-In-Class Dual Phosphodiesterase (PDE)3/4 Inhibitor, Is Equi-Effective as a Bronchodilator to Maximal Doses of Salbutamol in Asthmatics but with Fewer Adverse Events

**Day/Date:** SUNDAY, MAY 15, 2016

**Location:** Area A (Hall D) Moscone Centre (North Building) P36

**Time:** 9:00 AM-4:15 PM

**Session:** A31 - ASTHMA THERAPY: GLUCOCORTICOIDS AND BEYOND

**Session Type:** Thematic Poster Session

**Abstract ID 6811**

**Authors:** D. Singh, K.H. Abbott-Banner, F. Reid, K. Newman

**Title:** A Phase I, Randomised, Double Blind, Placebo Controlled, Study To Assess The Safety, Tolerability And Pharmacokinetics Of
About Verona Pharma

Verona Pharma’s lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulised treatment for acute exacerbations of COPD in the hospital setting. The drug is a dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both bronchodilator and anti-inflammatory effects, which are essential to the improvement of patients with COPD and asthma.

Verona Pharma is also building a broader portfolio of RPL554-containing products to maximise its benefit to patients and its value. This includes the very significant markets for COPD and asthma maintenance therapy. In addition, the Company is exploring the potential of the drug in different diseases, such as cystic fibrosis, where it is in pre-clinical testing and has received a Venture and Innovation Award from the UK Cystic Fibrosis Trust.

About ATS International Conference

The ATS International Conference is the home of pulmonary, critical care, and sleep professionals, from those in the earliest stages of their careers to people with research or strides in clinical care, which has gained them international recognition. Each year, nearly 14,000 of these professionals choose to attend, present, and learn about the latest advances, meet with colleagues from around the world, and strike new collaborations. It is truly where today’s science meets tomorrow’s care.

The International Conference is also multidisciplinary. Clinicians and researchers in many other fields attend the conference, thereby enriching conversations that lead to insights that ultimately improve patient care. Among the many other specialties represented in sessions at the International Conference are:

Allergy/Immunology, Behavioural Science, Cardiology, Environmental and Occupational Health, Infectious Disease, Paediatric, Pulmonary, Critical Care and Sleep

Equally important, the ATS International Conference gathers the entire health care team in one place to
share ideas across these medical and scientific disciplines. It is the ideal place for nurses, respiratory therapists, and hospitalists to discuss their experiences, challenges, and research so that all can learn about the latest advances in understanding pulmonary disease, critical illness, and sleep disorders. And of course, the International Conference is truly international: 40 percent of attendees arrive from laboratories and patient care centres beyond the United States.

Further information on the conference can be accessed via the following weblink:
http://conference.thoracic.org/

For further information, please contact:

Verona Pharma plc  
Tel: +44 (0) 20 7863 3300

Jan-Anders Karlsson, CEO

N+1 Singer
Tel: +44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

FTI Consulting
Tel: +44 (0)20 3727 1000

Simon Conway / Stephanie Cuthbert/ Natalie Garland-Collins

---

For further information please contact: Verona Pharma plc

Verona Pharma plc  
Tel: +44 (0) 20 3283 4200
info@veronapharma.com

N+1 Singer (Nominated Adviser and UK Broker)  
Tel: +44 (0)20 3283 4200

Optimum Strategic Communications
(European Media and Investor enquiries)
Tel: +44 (0) 203 950 9144
verona@optimumcomms.com

Argot Partners (Investor enquiries)
Tel. +1 646 644 9590
verona@argotpartners.com

---

About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. RPL554 has also shown anti-inflammatory effects and been well tolerated in clinical trials. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.

Forward Looking Statements
This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or
achievements to be materially different from our expectations expressed or implied by the forward-looking statements, including, but not limited to, the development of DPI and MDI formulations of RPL554 and the potential for these formulations to increase the market opportunity for the product, if approved.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.